Skip to content
ClinCalc Pro
Menu
Non-Benzodiazepine Hypnotic (Z-drug)

Zopiclone

Brand names: Zimovane

Zopiclone is a short-acting cyclopyrrolone ("Z-drug") hypnotic used for the short-term treatment of insomnia; this page concerns its use in older people, in whom a reduced dose is appropriate.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It enhances GABA-mediated inhibitory neurotransmission by binding at the benzodiazepine site of the GABA-A receptor, promoting sleep onset and continuity.

Prescribing in practice

  • In older patients the risk of daytime sedation, confusion, falls and fractures is markedly increased, so use the lowest effective dose for the shortest possible period and review the need promptly.
  • Tolerance and dependence develop with continued use, so prescribe for short courses only and avoid abrupt withdrawal after prolonged treatment.
  • Effects are potentiated by alcohol and other CNS depressants including opioids, and impairment may accumulate where hepatic or renal function is reduced.

Monitoring

No routine laboratory monitoring is required, but reassess sleep benefit, daytime functioning, falls risk and ongoing need at each review.

Counselling the patient

  • Take immediately before bed and only when a full night's sleep is possible, as it can cause next-day drowsiness.
  • Do not drink alcohol with this medicine and take care with driving or tasks needing alertness.
  • It is intended for short-term use only; speak to your prescriber before stopping if you have taken it regularly.

Evidence & guidelines

NICE guidance recommends Z-drugs only for short-term management of insomnia, and prescribing-safety advice emphasises lower doses and caution in older adults because of falls and confusion.

Reference: NICE CG49 (Insomnia); AGS Beers Criteria 2023; STOPP/START v3; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.